Sino orbital mucormycosis treated with fluconazole
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20250121Keywords:
Amphotericin B, Fluconazole, Invasive fungal sinusitis, MucormycosisAbstract
The successful treatment of mucormycosis requires; early diagnosis; reversal of underlying predisposing risk factors, if possible, surgical debridement, where applicable and prompt antifungal therapy. Amphotericin B is the gold standard antifungal treatment against mucormycosis to date. However, there are newer agents described recently like posaconazole and isavuconazole which can be used as an option in a few instances. Although amphotericin B especially the liposomal preparation is the preferred agent, the availability and the cost limit its use, especially in resource-limited setups. Generally, azole drugs, especially the first generations such as fluconazole, are not effective against zygomycetes. However, few reports showed complete recovery after use of fluconazole for adjunct treatment. Here we report on a 35-year-old newly diagnosed diabetic woman with Sinoorbital mucormycosis who has been treated with surgical debridement and intermittent bases of amphotericin B and was discharged home without optimal response but returned completely improved after three months of oral fluconazole.
Metrics
References
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(1):31-47. DOI: https://doi.org/10.1111/j.1470-9465.2004.00843.x
Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775-85. DOI: https://doi.org/10.1016/S1473-3099(05)70297-8
Selcen D, Secmeer G, Aysun S, Kanra G, Onerci M, Gököz A, et al. Mucormycosis in a diabetic child and its treatment with fluconazole: a case report. Turk J Pediatr. 1995;37(2):165-8.
Funada H, Miyake Y, Kanamori K, Okafuji K, Machi T, Matsuda T. Fluconazole therapy for pulmonary mucormycosis complicating acute leukemia. Jpn J Med. 1989;28(2):228-31. DOI: https://doi.org/10.2169/internalmedicine1962.28.228
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation and management. Clin Microbiol Rev. 2005;18(3):556-69. DOI: https://doi.org/10.1128/CMR.18.3.556-569.2005
Cho H-J, Jang M-S, Hong SD, Chung S-K, Kim HY, Dhong H-J. Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2015;29(1):48-53. DOI: https://doi.org/10.2500/ajra.2015.29.4115
Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010;12(6):423-9. DOI: https://doi.org/10.1007/s11908-010-0129-9
Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):1745-50. DOI: https://doi.org/10.1128/AAC.04435-14
Sipsas N V., Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi. 2018;4(3):1-17. DOI: https://doi.org/10.3390/jof4030090
Espinel-Ingroff A. Antifungal Agents. Encycl Microbiol Third Ed. 2009;187(7):205-22. DOI: https://doi.org/10.1016/B978-012373944-5.00331-X
Borba HHL, Steimbach LM, Riveros BS, Tonin FS, Ferreira VL, Bagatim BA de Q, et al. Cost‐effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. Mycoses. 2018;61(10):754-63. DOI: https://doi.org/10.1111/myc.12801
Smith C, Lee SC. Current treatments against mucormycosis and future directions. PLoS Pathog. 2022;18(10):1-7. DOI: https://doi.org/10.1371/journal.ppat.1010858
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-37. DOI: https://doi.org/10.1016/S1473-3099(16)00071-2
Vehreschild JJ, Birtel A, Vehreschild MJGT, Liss B, Farowski F, Kochanek M, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39(3):310-24. DOI: https://doi.org/10.3109/1040841X.2012.711741
Greenberg RN, Mullane K, Van Burik J-A, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126-33. DOI: https://doi.org/10.1128/AAC.50.1.126-133.2006
Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46(5):1581-2. DOI: https://doi.org/10.1128/AAC.46.5.1581-1582.2002
Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032-7. DOI: https://doi.org/10.1128/AAC.46.4.1032-1037.2002
Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother. 2001;48(6):919-21. DOI: https://doi.org/10.1093/jac/48.6.919
Downloads
Published
How to Cite
Issue
Section
